Trial Sponsored by:
SUBCUT-HF II: Use of a novel SUBCUTaneous preparation of furosemide to facilitate early supported discharge of patients with Heart Failure: a multicentre, phase II, randomised, parallel-group, active-comparator controlled trial (SUBCUT-HF II).
Many heart failure (HF) patients require frequent and often lengthy hospitalisation for treatment with intravenous (IV) diuretics, such as furosemide. In an attempt to address the need for hospital admission for administration of treatment, SQ Innovations has developed a new formulation of furosemide (SQIN-Furosemide) and a novel subcutaneous patch infusor drug delivery system (SQIN-Infusor).
This multicentre, open-label, randomised controlled trial will test the efficacy and safety of SQIN-Furosemide delivered via the new subcutaneous pump device in a primary care setting (compared to IV furosemide delivered in a secondary care setting) as part of a novel early supported discharge strategy for patients admitted to hospital with HF.
Recruitment status: Pending